Physician profile
Mark W Sohner
NPI 1780687624
$2,221.61
in general payments reported to CMS, 2019-2025
26 companies · $375 in 2025
The $375 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $72.93 · 2020: $114 · 2021: $136 · 2022: $359 · 2023: $421 · 2024: $744 · 2025: $375.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,540.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,540.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $418.92 | 2022-2024 | Vraylar |
| Novo Nordisk INC | $233.13 | 2022-2025 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $217.34 | 2020-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $211.82 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novartis Pharmaceuticals Corporation | $182.02 | 2020-2024 | |
| Abbott Laboratories | $123.29 | 2021-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $88.32 | 2019-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Amgen INC. | $74.52 | 2024-2025 | Otezla, Repatha, Repatha |
| Lilly USA, LLC | $68.57 | 2020-2025 | Mounjaro, Zepbound, Trulicity |
| Pfizer INC. | $66.89 | 2022-2025 | |
| Alkermes, INC. | $63.66 | 2019-2023 | Vivitrol |
| Bayer Healthcare Pharmaceuticals INC. | $58.76 | 2022-2024 | |
| Xeris Pharmaceuticals, INC. | $55.98 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $55.59 | 2022-2025 | Verquvo |
| Stryker Corporation | $44.63 | 2025 | Clottriever Bold Catheter |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $39.77 | 2025 | Caplyta |
| Indivior INC. | $36.70 | 2022-2025 | Sublocade |
| Exact Sciences Corporation | $31.69 | 2023 | Cologuard Collection Kit |
| Astellas Pharma US INC | $25.26 | 2024 | Veozah |
| Cranial Technologies, INC | $24.00 | 2023 | Doc Band |
| Insulet Corporation | $20.15 | 2024 | Omnipod |
| Avanir Pharmaceuticals, INC. | $19.52 | 2022 | |
| Corcept Therapeutics | $17.97 | 2024 | Korlym |
| Axsome Therapeutics, INC. | $15.65 | 2025 | Auvelity |
| Genentech USA, INC. | $15.23 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.23 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Sohner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.